Anaemia is a clinical hallmark of advanced kidney disease, characterized by insufficient erythropoiesis due to inadequate erythropoietin production in the kidney, inflammation and iron deficiency. Here, Mark Koury and Volker Haase discuss the hypoxic regulation of erythropoiesis and renal erythropoietin production, providing insight into the inter-relationships between erythropoietin synthesis, erythrocyte production, iron metabolism and inflammatory mediators. They also describe current clinical experience with pharmacologic activators of hypoxia-inducible factor signalling as an emerging approach to the treatment of renal anaemia.
- Mark J. Koury
- Volker H. Haase